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Background: Although organoboronic acids are efﬁcient high-throughput sugar sensors, they have not been
pursued for gut permeability studies. A modiﬁcation of the lactulose/mannitol assay is described by which
small intestinal permeability is assessed at the time of urine collection using a lactulose/riboﬂavin ratio.
Methods: Volunteers ingested 50 mg riboﬂavin and either 5 g mannitol or 10 g lactulose. Urine was collected for
6 hrs. Riboﬂavin was assayed by autoﬂuorescence. Riboﬂavin was removed by C18 solid phase extraction.
Lactulose andmannitolwere then assayed using 1,1’-bis(2-boronobenzyl)-4,4’-bipyridinium (4,4’oBBV) coupled
to the ﬂuorophore HPTS.
Results: The temporal proﬁle over 6 hrs for riboﬂavin paralleled mannitol. Riboﬂavin recovery in urine was
11.1 ± 1.9 % (mean ± SEM, n = 7), similar to mannitol. There was selective binding of 4,4’oBBV to lactulose,
likely involving cooperativity between the fructose and galactose moieties. Lower limits of detection and quan-
tiﬁcation were 90 and 364 μM. The lactulose assay was insensitive to other permeability probes (e.g., sucrose,
sucralose) while tolerating glucose or lactose. This assay can be adapted to automated systems. Stability of
4,4’oBBV exceeds 4 years.
Conclusions: Riboﬂavin measured by autoﬂuorescence combined with lactulose measured with 4,4’oBBV repre-
sents a useful new chemistry for rapid measurement of intestinal permeability with excellent stability, cost
and throughput beneﬁts.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd )./3.0/1. Introduction
Intestinal permeability allows for restrictive leakage of molecules
and ions below ~0.4 nm (MW ~250 Da) from the gut lumen into
blood circulation. This “paracellular” leakage occurs through tight junc-
tions between epithelial cells comprising the intestinal mucosa and
varies between individuals. Othermolecules pass through themicrovilli
of the epithelial cells by “transcellular” transport. Elevated paracellularor; NSAID, non-steroidal anti-
ulfonate; 4,4’oBBV, 1,1’-bis(2-
yl-1’-(2-boronobenzyl)-4,4’-
limit of detection; LLOQ, lower
; S/N, signal to noise ratio; SPE,
ile; MeOH, methanol; NAD(P),
artment of Medical Sciences.
Uppsala, Sweden. Tel.: +46 18
).
. This is an open access article underleakage has been implicated in many human disorders with immuno-
logical components, including type 1 diabetes mellitus [1], obesity and
type 2 diabetes mellitus [2], inﬂammatory bowel disease (i.e., Crohn's
disease and ulcerative colitis), celiac disease and irritable bowel syn-
drome [3–5], Parkinson's disease [6], environmental enteropathy [7]
and cancer [8]. There are comparable associations to laminitis in horses
[9]. Relevant to human and veterinary medicine are drug induced le-
sions and gut toxicity, as for instance by chemotherapy [10] or NSAIDs
[11]. Future researchers, drug developers and care givers working
with diseases not traditionally within the gastroenterology domain
will seek assistance from this discipline due to rising interest to quantify
gut permeability.
Gastroenterology units have limited resources to assay large num-
bers of urine samples for gut permeability to meet the anticipated
demand. The classical sugar absorption test for small intestinal perme-
ability uses lactulose to quantify abnormal paracellular leakage [12].
This is referenced against mannitol, giving a lactulose/mannitol ratio.
Althoughmannitol is absorbed by the paracellular route, a lowmannitol
value in this test is regarded to reﬂect nutrient deﬁciency through
reduction in nutrient transporters. Neither lactulose nor mannitol hasthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd )./3.0/
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tion. Typically, two different HPLC conﬁgurations (e.g., ion exchange
and reverse phase) are coupled to expensive detectors, such as mass
spectrometers [13]. Alternatively, NAD(P)H-coupled enzyme assays
are used [14,15], but require considerable time and cost.
Recent years have seen breakthroughs in molecular biology and
organic chemistry that should facilitate simpler, faster and less expen-
sive assessment of small intestinal permeability. For instance, riboﬂavin
has been found to be almost entirely absorbed through the type 2
riboﬂavin transporter (RFT2) at apical epithelial membranes in the
small intestine [16]. Loss of RFT2 expression results in severe riboﬂavin
deﬁciency [17]. Hence, appearance of riboﬂavin in urine during 6 hrs
after oral ingestion reﬂects absorption at duodenum and jejunum.
Riboﬂavin's intrinsic ﬂuorescence suggests a methodological advantage
over mannitol while reﬂecting absorption of an actual nutrient.
Much work has been done in using organoboronic acids to quantify
sugars [18–20]. Focus has been on glucose related measurements, and
these have had success in clinics; eight validated HbA1c assays employ
organoboranes [21]. However, organoboronic acids are typically more
sensitive to fructose and to lactulose, likely due to the fructose moiety.
Although less sensitive, they can also bind mannitol. We reasoned that
the intestinal permeability test could be simpliﬁed by 1) replacing
mannitol with riboﬂavin and 2) removal of riboﬂavin by C18 solid
phase extraction and measuring lactulose with an organoboronic acid
coupled to a ﬂuorophore. Beneﬁts include rapid assessment of urine
samples and negligible price. Reagents can be stored on ready toFig. 1. Synthesis of organoborane sugar sensors (a) and principuse plates in advance of measurement. We therefore synthesized the
bis-boronic acid appended viologen 1,1’-bis(2-boronobenzyl)-4,4’-
bipyridinium (compound 1)(4,4’oBBV). For comparison, a mono-
boronic analog (compound 3)(4,4’oMBV) with increased water solubil-
ity was also synthesized (Fig. 1). Both can be coupled to ﬂuorophores.
These were ﬁrst used to determine if riboﬂavin can replace mannitol
and then to quantify lactulose.
2. Methods
2.1. Preparation of boronic acid viologens 1 (4,4’oBBV) and 3 (4,4’oMBV)
The reaction schemewith compound numbering is shown in Fig. 1a.
Synthesis of 4,4’oBBV was as we reported earlier [22]. For 4,4’oMBV,
2-bromomethylphenyl boronic acid was reacted with excess 4,4’-
bipyridyl in acetone to afford themono-substituted 4,4’bipyridyl adduct
(compound 2). Combining excess compound 2with benzyl bromide in
a solvent mixture of MeCN and MeOH yielded 4,4’oMBV (compound
3) after precipitation from the reaction mixture with acetone. Reagents
and conditions were: (i) dimethylformamide, 55 °C, 48 hrs, 90% (com-
pound 1); (ii) acetone, 25 °C, 2 hrs, 70% (compound 2); (iii) MeCN,
MeOH, 55 °C, 24 hrs, 86% (compound 3). Chemicals were from Sigma
Aldrich (St Louis MO, USA) unless stated otherwise.
Fig. 1b illustrates themolecularmechanismbehind the organoborane
based ﬂuorescent lactulose assay. The sensing ensemble is comprised
of an anionic ﬂuorophore, 8-hydroxypyrene-1,3,6-trisulfonic acidle of ﬂuorescence assay for urine lactulose or mannitol (b).
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HPTS forms a weak ground state complex with the cationic viologen
sugar receptor, quenching its ﬂuorescence. Ground state complex
formation between the anionic ﬂuorophore and cationic viologen sugar
receptor facilitates an electron transfer from the ﬂuorophore to the
viologen, decreasing ﬂuorescence. At pH ~7.4, the cationic boronic acid
viologen receptor has a high intrinsic afﬁnity for cis-diols, which upon
binding, partially neutralizes the charge of the viologen. This is caused
by an equilibrium shift from the neutral boronic acid to the anionic
boronate ester, lowering its afﬁnity for HPTS, giving increased
ﬂuorescence.
2.2. Baseline absorbance spectra of urine
Because the assay uses spectroscopic methods, urine samples were
evaluated for interfering absorbance. Urine was collected from volun-
teers, including subjects with suspected gut hyperpermeability. They
were instructed to drink 0.5–1.0 L water the night before and in the
morning ~3 hrs prior to sample collection. The ﬁrst morning urine
was voided. No food or additional beverages were consumed until
after the baseline sample was collected. This reﬂects current practice
prior to initiating the permeability test. Absorbance was scanned from
380 to 700 nm at the time of collection. Below 380 nm, samples are
essentially opaque. Absorbance is negligible from 700 to 1000 nm.
2.3. Temperature and solubility of reagents
A BioRad C1000 thermal cycler with CyberGreen ﬁlters (Exc 470, Em
520 nm) was used to determine the thermal properties of the assay. A
smaller set of samples were checked at 404/535 nm on the plate reader
normally used for the permeability test (see below). Aliquots of 6 μL of a
4X premix containing 500 μM 4,4’oBBV and 16 μM HPTS in 100 mM
sodium phosphate buffer at pH 7.4 were distributed onto PCR plates
(HSP-9601, BioRad, Hercules, CA, USA). Then, 18 μL urine samples con-
taining serially diluted 0 to 80 mM lactulose were distributed into the
wells. Plates were sealed with clear plate tape and assayed from 5 to
70 °C.
2.4. Permeability test in humans
Subjects consumed 0.5–1.0 L water the night before and in the
morning ~3 hr prior to sample collection. The ﬁrst morning urine was
voided. No food or other beverages were consumed prior to the test.
Permeability probes were ingested after baseline urine collection.
Doses were 50 mg riboﬂavin (Freeda Vitamins Inc, Long Island City,
NY, USA) and 5 g mannitol or 10 g lactulose (15 mL at 0.67 mg/mL;
Meda AB, Solna Sweden). Test subjects were permitted to drink water
or coffee as desired. Light snacks were permitted after the fourth hr.
Urine volumes were recorded and 50 mL was retained for analysis.
Studies were carried out in Sweden according to ethical approval Dnr
2010/184 held at Uppsala University, Sweden. In this jurisdiction,
lactulose, mannitol and riboﬂavin are available over the counter.
2.5. Urine assays
2.5.1. Sample collection
Volume of urine collected was recorded and 50 mL was ﬁrst centri-
fuged 2500 RCF, 4 °C, 10min. 100 μL supernatant was set aside for ribo-
ﬂavin analysis, the remaining supernatant was frozen at −20 °C for
later mannitol or lactulose analyses.
2.5.2. Riboﬂavin assay
The above 100 μL urine set aside and standards prepared in pooled
baseline samples were diluted in 900 μL EtOH, vortexed and centri-
fuged. Supernatants were pipetted 40 μL/well in duplicate into plates
(#3694, Corning, USA). Fluorescence (Exc/Em 450/580 nm) was readon a plate reader (Inﬁnite M200Pro, Tecan, Switzerland). Signal to
noise (S/N) was higher at 580 nm than at the 530 nm emission maxi-
mum. Concentration was calculated as mg/mL and multiplied by total
urine volume in mL, giving total mg in urine. The mg in urine/mg
ingested × 100 yielded % ingested.2.5.3. C18 solid phase extraction of samples for lactulose and mannitol
To remove riboﬂavin and other colored components, 2mL urinewas
processed twice through solid phase extraction (SPE) using 500mg C18
columns ﬁtted onto a Waters/Millipore SPE vacuum manifold (max
−50 kPa, ~0.5 mL/min). The SPE column was cleaned with MeOH and
H2O between runs. Mannitol and lactulose recovery were both ~91%.
Data were corrected for a 9% loss. After SPE, samples were directed to
the various assays.2.5.4. Viologen method for lactulose and mannitol permeability in humans
Ready-made assay 96 well plates were prepared (#3694, Corning,
USA). A 4X premix buffer was prepared (0.1 M sodium phosphate, 0.1
M HEPES, 0.04% Triton X-100, pH 7.4). To this was added HPTS
(16 μM) and quencher (1.6 mM 4,4’oBBV or 2.0 mM 4,4’oMBV), each
4 times above ﬁnal concentration. The different viologen concentrations
were chosen to achieve similar extents of quenching in the absence of
sugar (~20% of free ﬂuorophore) while preserving S/N. Blank wells
were given 10 μL 4X premix buffer with neither HPTS nor viologen.
Some wells received 16 μM HPTS without quencher to determine
maximum possible ﬂuorescence. All other wells received 10 μL of the
complete 4X premix. Those premixes containing 4,4’oBBV were contin-
uously vortexed because themixture is a suspension. Plates were sealed
with plate tape and stored at 4 °C until use.
Upon running an assay, 30 μL of mannitol or lactulose standards or
samples were pipetted into wells. To explore selectivity, concentra-
tion dependencieswere determined for the following analytes: sucrose,
sucralose, turanose, galactose, fructose, glucose and lactose, each pre-
pared and run in same way. Final reagent concentrations were 4 μM
HPTS and 400 μM 4,4’oBBV or 500 μM 4,4’oMBV. Urine samples were
placed in both blank wells (for individual sample blanking) and wells
containing complete 4X premix. Plates were put on a shaker for 1 hr,
RT. During this time, sugars interacted with the HPTS-viologen com-
plex, liberating HPTS into solution. Plates were then centrifuged at
2500 RCF, 10 min, RT to pull down remaining HPTS-quencher partic-
ulate matter; plate tape was removed and ﬂuorescence read on a
plate reader (TecanM-200 Inﬁnite, gain 70, 404/535 nm). The height
was adjusted to read from the top of the solution (18 mm). This wave-
length combination is pH insensitive and poorly affected by any residual
riboﬂavin or endogenous ﬂuorophores that might still be present
after C18 SPE. A Marquardt 4-parameter curve ﬁt was used. Sugar
concentrations were calculated as g/mL and multiplied by total
urine volume in mL, giving total g in urine. Values were corrected
for % recovery from the C18 SPE step. The g in urine/g ingested
× 100 yielded % ingested. Lactulose measurements were conﬁrmed
by enzyme assay [14]. Mannitol measurements were conﬁrmed by
HPLC-ELSD using a C8 pre-column and Prevail Carbohydrate ES 5 μ
250 × 4.6 mm column (Grace Davison Discovery Sciences, IL, USA)
with 80:20 MeCN/H2O.2.5.5. Statistics
The lower limit of detection (LLOD) was deﬁned as the analyte
concentration in the urine sample at which ﬂuorescence intensity in
the assay was 3 standard deviations above the mean baseline ﬂuores-
cence. Similarly, the lower limit of quantiﬁcation (LLOQ) was deﬁned
as 10 standard deviations above the mean baseline ﬂuorescence. CV%
was determined by averaging sets of samples each measured in 4
wells. Results are given as mean ± SEM.
Fig. 2. Concentration dependency of the viologen based assay with human urine. (a) Standard curves for lactulose and mannitol using 4,4’oBBV demonstrating strongest sensitivity to
lactulose and strong discrimination against sucrose and sucralose. Note the response to the sucrose analog turanose inwhich C3 of the fructosemoiety is occupied by the glycosylic linkage
to glucose and cannot take part in binding to boronic acid. (b) Corresponding standard curves for 4,4’oMBV showing similar pattern of responses albeit with weaker changes in ﬂuores-
cence. (c) Auxiliary data showing comparatively stronger sensitivity of fructose over galactose, the twomoieties of lactulose. Note the lack of sensitivity of this assay system for glucose and
lactose, which can appear in some patient urine samples. (d) Corresponding data for 4,4’oMBV. Data points are mean ± SEM, n = 3. Concentrations are threefold serial dilutions from
10 mM. Lowest data points are without addition of analytes.
Table 1
Lower limits of detection (LLOD) and quantiﬁcation (LLOQ), range and CV% for riboﬂavin,
lactulose andmannitol in human urine. Estimated from 3 separate runs (3 different occa-
sions) in which all parameters were assayed in parallel. All data points were measured in
duplicate on all occasions. Background (assay noise level) and standard deviation for
organoboranes were deﬁned as baseline urine with HPTS (404/535 nm) and viologen in
the absence of sugar. This 0 μM sugar standard is the point at which maximum HPTS
quench is achieved. Values for 4,4'oBBV are averages for 2 different batches.
Intl. Quench LLOD LLOQ RANGE
Parameter %max μM μM μM CV%
Riboﬂavin
N/A b0.10 0.30 29.3 ± 6.8 b5
Lactulose 4,4'oBBV 24 90 364 132 ± 59 3.3
4,4'oMBV 16 108 704
Mannitol
4,4'oBBV 24 416 860 3929 ± 972 2.4
4,4'oMBV 16 354 1250
Initial quench: HPTS ﬂuorescence in presence of quencher and absence of sugar (maxi-
mum achievable quench) as a percent of maximum possible ﬂuorescence with 4 μM
free HPTS in absence of any quencher. LLOD: analyte concentration in original urine
sample (as opposed to ﬁnal concentration in the assay) at which the ﬂuorescence signal
equals or exceeds 3 standard deviations above mean assay noise level. LLOQ: analyte
concentration in original urine sample at which the ﬂuorescence signal equals or exceeds
10 standard deviations above mean assay noise level. Range: urine concentrations found
in healthy volunteers before transforming data to % ingested. Mean ± SEM. CV%: intra-
assay coefﬁcient of variation for samples.
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3.1. Concentration dependencies and selectivity
Fig. 2 shows standard curves used to determine limits of detection
and quantiﬁcation for lactulose and mannitol as well as comparisons
to other sugars. Limits of detection and quantiﬁcation are tabulated in
Table 1. Also shown are concentration ranges and intra-assay CV%. To
illustrate the sensitivity of the assay relative to values obtained in
urine samples, the range of concentrations are given instead of %
ingested normally stated in a clinical report. The riboﬂavin assay was
at least two orders of magnitude more sensitive than required using
the current 50mg dose. Because this assaymeasures intrinsic riboﬂavin
ﬂuorescence, standards were linear. For the viologen based sugar
assays, the initial quench (as percent of maximum HPTS ﬂuorescence
in absence of viologen) indicates that HPTS ﬂuorescence is strongly
quenched at the lowest (0 μM) sugar concentration of the standard
curve. This also illustrates that 4,4’oMBV is a less potent quencher
than 4,4’oBBV, requiring about 20% higher concentration to achieve
the same extent of quenching. As sugar concentration increased,
4,4’oBBV showed stronger de-quenching than 4,4’oMBV, indicating
4,4’oBBV has superior ability to resolve different sugar concentrations.
Gut permeability assays therefore used 4,4’oBBV. Given that lactulose
Fig. 3. a) Baseline absorbance spectra from 5 human volunteers prior to ingesting permeability probes. Baseline urine samples were used in order to highlight removal of endogenous
chromophores. Due to spectral overlap, the result of solid phase extraction (SPE) is only shown for the ﬁrst two subjects, the ﬁrst having the highest absorbance obtained in this study.
b) Temperature dependency of viologen based ﬂuorescence assay. Magnitude of increase in ﬂuorescence remains relatively constant across the temperature range 10-50 ºC. Some of
the signal increase is an intrinsic property of HPTS, as seen with 4 µMHPTS in the absence of viologen (open triangle with highest signal). In the absence of sugar at or below 5 ºC, signal
obtained can dip below blank values, presumably due to absorbance in presence of weaker ﬂuorescence. Data points are mean ± SEM, n= 6. Samples are baseline urine samples spiked
with lactulose.
Fig. 4. Temporal measurement of mannitol and riboﬂavin in healthy human volunteers.
Mannitol was measured using 4,4’oBBV and riboﬂavin by autoﬂuorescence (450/580 nm).
All data points are mean ± SEM. Riboﬂavin recovery over 6 hours was 11.1 ± 1.9%.
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also made it better suited for the gut permeability test. The low CV%
achieved (intra-assay) throughout is afforded by the limited number
of pipetting steps.
3.2. Effectiveness of C18 cleanup
Fig. 3a shows the absorbance of a typical range of urine samples as
they are received and the effectiveness of C18 solid phase extraction.
After 2 extraction cycles, at which stage no further cleanup can be
achieved, urine remained opaque below ~380 nm and negligible
above 700 nm. Variation in absorbance between samples is largely
removed. This proved adequate for the 404/535 nm wavelengths of
HPTS. Background ﬂuorescence was reduced to ~20 times below
the bottom of the standard curves.
3.3. Temperature and solubility
Temperature and solubility of 4,4’oBBV were evaluated because
boronic acid moieties of organoboranes generally confer reduced solu-
bility on organoboranes. We have noted a precipitate in the presence
of HPTS. Solubility increases in the presence of lactulose. Previous stud-
ies using homogeneous buffer systems indicated the optimal quencher/
dye ratio to be 125:1 with 500 μM 4,4’oBBV. This was among the best
quencher-dye pairings for lactulose measurements. It was also known
to result in a precipitate that affected assay performance, perhaps due
to theplanar symmetry of 4,4’oBBV.We therefore examined theproper-
ties of the 4,4’oBBV-HPTS precipitate. It proved to be inversely propor-
tional to sugar concentration and HPTS ﬂuorescence. Following
centrifugation, ~90% of HPTS and a similar amount of 4,4’oBBV was
trapped in the pellet. When used to assay sugars, the supernatant of
the 4X premix performed poorly compared to the re-suspended precip-
itate due to loss of most of the ﬂuorophore and viologen. The thermal
dependency of the combination of 500 μM 4,4’oBBV and 4 μM HPTS
(ﬁnal concentrations) for lactulose standards in urine is illustrated in
Fig. 3b. When temperature and sugar concentration are low, HPTS ﬂuo-
rescence approaches that of the blank. The absorbance contributed by
4,4’oBBV and quenched HPTS in the absence of ﬂuorescence leads to
values below the blank, yielding negative values after blank subtraction.
A ﬁnal concentration of 4,4’oBBV (400 μM)was therefore chosen for as-
says, givinghigher S/N at low sugar concentrations. Establishing that the
precipitate is a component of the assay led to the practice of centrifugingthe plate prior to reading (2500 RCF, 10 min). The plate readerwas then
conﬁgured to read from the top of the solution, thus removing any inﬂu-
ence of residual unreacted precipitate. Separate experiments conﬁrmed
that this is relevant for the pH insensitive 404/535 nm wavelengths
used in an actual permeability test.
3.4. Temporal overlap of mannitol and riboﬂavin
Fig. 4 shows temporal appearance of riboﬂavin and mannitol in
urine when sampled hourly after ingestion. Riboﬂavin consistently
appeared somewhat later than mannitol. Both riboﬂavin and mannitol
returned to baseline at about 6 hrs, demonstrating that 6 hrs is an
acceptable cutoff for studies of small intestinal permeability. Thus, ribo-
ﬂavin, a true nutrient absorbed by way of transport through RFT2,
should be able to replace mannitol, which is used as a surrogate marker
for nutrient malabsorption, as in active celiac disease.
3.5. Lactulose and the lactulose/riboﬂavin ratio
Table 2 lists results for lactulose measured in 13 human volunteers
using 4,4’oBBV and riboﬂavin for the time interval 0–6 hrs. Three of
Table 2
Lactulose/Riboﬂavin ratios for healthy (asymptomatic) adult human volunteers.
Participants declared no gastrointestinal disturbances and had not been taking NSAIDs
or alcoholic beverages immediately prior to or during test (n = 10). Three of these
volunteers performed a second test, ingesting water without lactulose or riboﬂavin to
establish a baseline (B1–B3). Doses were 10 g lactulose and 50 mg riboﬂavin. Urine was
collected in a single container for 6 hrs following ingestion, representing small intestinal
absorption. For comparison, 3 volunteers who had been taking NSAIDs for chronic pain
(otherwise healthy) are listed separately.
Lactulose Riboﬂavin Lactulose/Riboﬂavin
Sample Age Gender % Ingested % Ingested Ratio
B1 33 Female ND ND -
B2 49 Male ND ND -
B3 50 Male ND ND -
——
1 50 Male 0.268 16.931 0.016
2 50 Male 0.212 9.850 0.022
3 49 Male 0.227 9.300 0.025
4 28 Female 0.149 9.383 0.016
5 41 Female 0.175 6.406 0.027
6 28 Female 0.216 9.469 0.023
7 33 Female 0.142 9.467 0.015
8 20 Male 0.771 17.150 0.045
9 45 Female 0.155 16.136 0.010
10 31 Male 0.501 13.356 0.037
Mean 38 0.282 11.745 0.024
SEM 3 0.064 1.211 0.003
Volunteers taking NSAIDs
11 48 Male 2.240 2.930 0.765
12 59 Male 0.319 10.810 0.030
13 60 Female 0.929 16.701 0.056
ND = not detectable. Signal from rawdatawas belowdetection limit and not signiﬁcantly
different from buffer without lactulose or riboﬂavin.
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ingesting lactulose or riboﬂavin to establish a baseline (B1-B3). Three
volunteers had been taking NSAIDs for chronic pain; two of these
were outliers in the assays, presumably due to NSAID use. The correla-
tion plot shown in Fig. 5 illustrates the ability of the 4,4’oBBVbasedﬂuo-
rescence assay to quantify urine lactulose with results comparable to
the established enzymatic assay (n = 24 urine samples).Fig. 5. Correlation between the novel 4,4’oBBV ﬂuorescence lactulose assay and con-
ventional enzyme assay. Standards and 24 urine samples were processed through
both assays. The novel 4,4’oBBV based assaywas run in quadruplicates to ensure accurate
measurement of sample CVs, which was 12% for this dataset. The enzyme assay was
run in duplicates with a CV of 8%.4. Discussion
It was hoped 4,4’oMBVwould perform aswell as 4,4’oBBV because it
is ~20 timesmore soluble. In a separate series of experiments reproduc-
ing the results of Fig. 2, it was found that a 4,4’-viologen lacking boronic
acidswas an evenweaker quencher. Thismeans that boronic acids facil-
itate HPTS quenching and that facilitation is lost when sugars react with
boronic acid groups. Two boronic acids provide more facilitation to
quenching, and as a result, more capacity to de-quench in the presence
of sugar.
At alkaline pH, boronic acids act by reversible formation of cyclic
esterswith selective diolswithin saccharides.We devised two viologens
demonstrating high sensitivity and selectivity for lactulose. The binding
mechanism of boronic acids to diols has been investigated for glucose
and fructose [23,24]. 13C-NMR demonstrated that phenylboronic acid
forms the β-D-fructofuranose complex or β-D-fructopyranose at C2
and C3 under alkaline conditions similar to this study. Since lactulose
contains a fructose moiety in which hydroxyls at C2 and C3 are avail-
able, the present viologenswere anticipated to interact at these carbons,
with galactose potentially contributing a smaller component. Unexpect-
edly, turanose, a glucose-(1→ 3)-fructose analog of sucrose differing
only in the glycosylic linkage at C3of fructose, gave ~20% of the lactulose
ﬂuorescence, and ~30% of fructose, whereas sucrose gave no signal.
Hence, C3 of the fructose moiety likely accounts for most of the boronic
acid binding to lactulose in this assay system, but is not absolutely
required. Lactulose gave ~20% stronger signal than fructose while
equimolar amounts of fructose with galactose gave a higher signal than
lactulose. Relative selectivity of 4,4’oBBV was lactulose N fructose N
galactose, whereas 4,4’oMBV was similar for lactulose and fructose.
We therefore propose that lactulose binds 4,4’oBBV in a bidentate
(cooperative) fashion involving both the fructose and galactose moie-
ties, explaining the selectivity and sensitivity of this assay for lactulose.
Among the concerns in performing any light based assay on urine is
interfering absorbance and ﬂuorescence. For samples destined for the
viologen assay, the C18 SPE cleanup procedure proved sufﬁcient to
eliminate riboﬂavin as well as endogenous ﬂuorescence to the extent
of being negligible.When high throughput is desired, 96 or 384 well ﬁl-
ter plates loaded with C18 may be used with a plate centrifuge.
The upward trend in signal intensity was parallel across all sugar
concentrations with rising temperature. This trend was seen with
other sugars and with 4,4’oMBV (data not shown). Hence, nothing is
achieved by straying from RT, albeit temperature must be stable. The
problem of limited solubility of 4,4’oBBV-HPTSwas solved by centrifug-
ing the plate and reading ﬂuorescence from the top of the solution.
Sucrose and sucralose are often used in permeability tests to assess
gastroduodenal and colonic permeability. Since neither sucrose nor
sucralose interfere with the viologen based method, there are no obsta-
cles to their inclusion in clinical studies. Note also that 4,4’oBBV gave
essentially no response to 10 mM glucose or lactose. Their presence in
urine does not complicate this assay. The mere presence of cis-diols is
not sufﬁcient to generate a signal.
Riboﬂavin, reﬂecting transcellular absorptive capacity of villi, can
replace mannitol. Despite anticipated concerns for variation due to
metabolism, etc., riboﬂavin values in healthy subjects varied, if any-
thing, less than mannitol. The delay in appearance of riboﬂavin relative
mannitol might reﬂect differences in where the initial uptake occurs.
Riboﬂavin is conﬁned to uptake through the RFT2 transporter and
may more strongly correlate with condition of villi tips of duodenum
and jejunum. Because RFT2 transport is down-regulated in somegastro-
intestinal diseases, riboﬂavin measurements should serve to identify
such conditions. The range in riboﬂavin values obtained here suggests
a narrow range of values in healthy individuals.
Regarding predictive value, the three volunteers taking NSAIDs in
Table 2 varied in different ways. Subject 11, who had been taking two
different NSAIDs during several years for chronic pain, had the highest
lactulose recovery as well as lowest riboﬂavin recoveries thus far.
121A. Resendez et al. / Clinica Chimica Acta 439 (2015) 115–121Subject 12 was an asymptomatic type 2 diabetic taking occasional low
doses of NSAIDs with recovery values comparable to healthy controls.
Subject 13 had the second highest lactulose recovery seen to date,
while riboﬂavin absorption could not have been impaired. Subjects 11
and 13 were originally recruited as healthy volunteers. Their use of
NSAIDs was discovered upon queering after the data were obtained.
These cases indicate the capacity to identify increased small intestinal
permeability. Subject 11 further suggests detection of villi tip architec-
tural damage.
5. Conclusions
Reagent costs for the viologenmethod togetherwith riboﬂavinwere
negligible, b1 USD/sample. Reagent costs for enzyme assays (lactulose
and mannitol) are ~25 USD/sample, while requiring more time. The
viologen assay permits routine monitoring, which has not been feasible
previously. Viologens have remained stable for N4 years. In conclu-
sion, organoboronic acids show potential to study intestinal perme-
ability, in this case together with riboﬂavin. Future developments of
organoborane chemistry for this application are anticipated.
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